Immunocytochemical localization of HLA-DR in human islets of Langerhans

Rodolfo Alejandro, F. L. Shienvold, S. Vaerewyck Hajek, U. Ryan, J. Miller, D. H. Mintz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Previous reports of allogeneic transplantation studies in rodents have postulated that the primary carriers of Ia antigen in islets of Langerhans are passenger leukocytes. We sought to demonstrate directly the localization of the analogous human antigen, HLA-DR, in islet-enriched fractions (IEFs), utilizing a nonpolymorphic monoclonal anti-DR (αDR) antibody. The presence of DR in the IEFs was first demonstrated by radioimmunobinding assay. Light microscopic immunocytochemistry, in frozen sections of intact (unfixed) human pancreas, revealed a staining pattern suggestive of a vascular distribution of DR in islets. Ultrastructural localization of DR was then carried out by indirect immunoperoxidase labeling in the presence of NaN3 (to prevent internalization of bound αDR). The major site of DR expression in the islet was the endothelial cell surface. Endocrine cells were entirely of αDR binding. Nonislet endothelium was also heavily labeled, but acinar and ductal cells were completely negative. Leukocytes bound αDR but were relatively rare in the IEFs. Human islets, therefore, clearly express HLA-DR, but predominantly on insular endothelial cells. Isolation of pure endocrine cell populations, specifically free of endothelium, would appear to be a rational approach to reducing immunogenicity in allogeneic transplantation.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalDiabetes
Volume31
Issue numberSuppl. 4
StatePublished - Oct 5 1982

Fingerprint

HLA-DR Antigens
Islets of Langerhans
Endocrine Cells
Homologous Transplantation
Endothelium
Leukocytes
Endothelial Cells
Sodium Azide
Acinar Cells
Histocompatibility Antigens Class II
Frozen Sections
Blood Vessels
Pancreas
Rodentia
Immunohistochemistry
Staining and Labeling
Light
Antibodies
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Alejandro, R., Shienvold, F. L., Vaerewyck Hajek, S., Ryan, U., Miller, J., & Mintz, D. H. (1982). Immunocytochemical localization of HLA-DR in human islets of Langerhans. Diabetes, 31(Suppl. 4), 17-22.

Immunocytochemical localization of HLA-DR in human islets of Langerhans. / Alejandro, Rodolfo; Shienvold, F. L.; Vaerewyck Hajek, S.; Ryan, U.; Miller, J.; Mintz, D. H.

In: Diabetes, Vol. 31, No. Suppl. 4, 05.10.1982, p. 17-22.

Research output: Contribution to journalArticle

Alejandro, R, Shienvold, FL, Vaerewyck Hajek, S, Ryan, U, Miller, J & Mintz, DH 1982, 'Immunocytochemical localization of HLA-DR in human islets of Langerhans', Diabetes, vol. 31, no. Suppl. 4, pp. 17-22.
Alejandro R, Shienvold FL, Vaerewyck Hajek S, Ryan U, Miller J, Mintz DH. Immunocytochemical localization of HLA-DR in human islets of Langerhans. Diabetes. 1982 Oct 5;31(Suppl. 4):17-22.
Alejandro, Rodolfo ; Shienvold, F. L. ; Vaerewyck Hajek, S. ; Ryan, U. ; Miller, J. ; Mintz, D. H. / Immunocytochemical localization of HLA-DR in human islets of Langerhans. In: Diabetes. 1982 ; Vol. 31, No. Suppl. 4. pp. 17-22.
@article{2f57e34c6b214faa8dd5bb26bb9cfc83,
title = "Immunocytochemical localization of HLA-DR in human islets of Langerhans",
abstract = "Previous reports of allogeneic transplantation studies in rodents have postulated that the primary carriers of Ia antigen in islets of Langerhans are passenger leukocytes. We sought to demonstrate directly the localization of the analogous human antigen, HLA-DR, in islet-enriched fractions (IEFs), utilizing a nonpolymorphic monoclonal anti-DR (αDR) antibody. The presence of DR in the IEFs was first demonstrated by radioimmunobinding assay. Light microscopic immunocytochemistry, in frozen sections of intact (unfixed) human pancreas, revealed a staining pattern suggestive of a vascular distribution of DR in islets. Ultrastructural localization of DR was then carried out by indirect immunoperoxidase labeling in the presence of NaN3 (to prevent internalization of bound αDR). The major site of DR expression in the islet was the endothelial cell surface. Endocrine cells were entirely of αDR binding. Nonislet endothelium was also heavily labeled, but acinar and ductal cells were completely negative. Leukocytes bound αDR but were relatively rare in the IEFs. Human islets, therefore, clearly express HLA-DR, but predominantly on insular endothelial cells. Isolation of pure endocrine cell populations, specifically free of endothelium, would appear to be a rational approach to reducing immunogenicity in allogeneic transplantation.",
author = "Rodolfo Alejandro and Shienvold, {F. L.} and {Vaerewyck Hajek}, S. and U. Ryan and J. Miller and Mintz, {D. H.}",
year = "1982",
month = "10",
day = "5",
language = "English",
volume = "31",
pages = "17--22",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "Suppl. 4",

}

TY - JOUR

T1 - Immunocytochemical localization of HLA-DR in human islets of Langerhans

AU - Alejandro, Rodolfo

AU - Shienvold, F. L.

AU - Vaerewyck Hajek, S.

AU - Ryan, U.

AU - Miller, J.

AU - Mintz, D. H.

PY - 1982/10/5

Y1 - 1982/10/5

N2 - Previous reports of allogeneic transplantation studies in rodents have postulated that the primary carriers of Ia antigen in islets of Langerhans are passenger leukocytes. We sought to demonstrate directly the localization of the analogous human antigen, HLA-DR, in islet-enriched fractions (IEFs), utilizing a nonpolymorphic monoclonal anti-DR (αDR) antibody. The presence of DR in the IEFs was first demonstrated by radioimmunobinding assay. Light microscopic immunocytochemistry, in frozen sections of intact (unfixed) human pancreas, revealed a staining pattern suggestive of a vascular distribution of DR in islets. Ultrastructural localization of DR was then carried out by indirect immunoperoxidase labeling in the presence of NaN3 (to prevent internalization of bound αDR). The major site of DR expression in the islet was the endothelial cell surface. Endocrine cells were entirely of αDR binding. Nonislet endothelium was also heavily labeled, but acinar and ductal cells were completely negative. Leukocytes bound αDR but were relatively rare in the IEFs. Human islets, therefore, clearly express HLA-DR, but predominantly on insular endothelial cells. Isolation of pure endocrine cell populations, specifically free of endothelium, would appear to be a rational approach to reducing immunogenicity in allogeneic transplantation.

AB - Previous reports of allogeneic transplantation studies in rodents have postulated that the primary carriers of Ia antigen in islets of Langerhans are passenger leukocytes. We sought to demonstrate directly the localization of the analogous human antigen, HLA-DR, in islet-enriched fractions (IEFs), utilizing a nonpolymorphic monoclonal anti-DR (αDR) antibody. The presence of DR in the IEFs was first demonstrated by radioimmunobinding assay. Light microscopic immunocytochemistry, in frozen sections of intact (unfixed) human pancreas, revealed a staining pattern suggestive of a vascular distribution of DR in islets. Ultrastructural localization of DR was then carried out by indirect immunoperoxidase labeling in the presence of NaN3 (to prevent internalization of bound αDR). The major site of DR expression in the islet was the endothelial cell surface. Endocrine cells were entirely of αDR binding. Nonislet endothelium was also heavily labeled, but acinar and ductal cells were completely negative. Leukocytes bound αDR but were relatively rare in the IEFs. Human islets, therefore, clearly express HLA-DR, but predominantly on insular endothelial cells. Isolation of pure endocrine cell populations, specifically free of endothelium, would appear to be a rational approach to reducing immunogenicity in allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0020084720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020084720&partnerID=8YFLogxK

M3 - Article

C2 - 6762305

AN - SCOPUS:0020084720

VL - 31

SP - 17

EP - 22

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - Suppl. 4

ER -